docturnal

Docturnal Private Limited, established in April 2016, specializes in point of care screening for lung health with a primary focus on infectious diseases. The company's flagship product is a solution for TB screening and detection. Their product portfolio also includes solutions for Pneumonia, Covid-19, COPD, and Asthma, with a pipeline of lung-based ailments that can be identified by an aural component. Docturnal's products are designed to make disease detection easy and hassle-free, ensuring accessibility and affordability to the last mile. The company partners with confirmatory diagnostic providers offering RT PCR tests, and all their solutions have undergone third-party clinical validation. Docturnal's mission aligns with combating diseases that are leading causes of death in developing nations. The company operates in the healthcare market, serving both individual patients and healthcare providers. Their business model is based on selling their screening solutions to healthcare providers and diagnostic centers, generating revenue through product sales and partnerships. Docturnal has been recognized for its digital transformation initiatives and has received seed funding and mentorship from various programs, including the IIIT H incubator.

Keywords: TB screening, Pneumonia detection, Covid-19 solutions, COPD management, Asthma exacerbations, lung health, infectious diseases, point of care, affordable healthcare, clinical validation.